The in vitro generation of Ph1+ ALL-specific HLA-A24-restricted cytotoxic T lymphocytes using a synthetic 16 mer minor bcr-abl peptide

Leukemia Research

Volumn 27, Issue 3, 2003, Pages 253-257

  Hagihara, Masao ^a   Tsuchiya, Takahide ^a   Hyodo, Osamu ^b   Ueda, Yoko ^a   Tazume, Kei ^a   Gansuvd, Balgansuren ^a   Kato, Shunichi ^a   Hotta, Tomomitsu ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKAI UNIVERSITY HOSPITAL   (Japan)

Author keywords

Cytotoxic T lymphocytes; Dendritic cell; HLA A24; Peptide; Ph1 ALL

Indexed keywords

BCR ABL PROTEIN; CD8 ANTIGEN; GAMMA INTERFERON; HLA A24 ANTIGEN; HLA ANTIGEN CLASS 1; MONOCLONAL ANTIBODY;

ACUTE LYMPHOCYTIC LEUKEMIA; ANTIGEN BINDING; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HLA MATCHING; HUMAN; HUMAN CELL; IN VITRO STUDY; MONONUCLEAR CELL; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROTEIN MOTIF;

ANTIGEN PRESENTATION; CD8-POSITIVE T-LYMPHOCYTES; COCULTURE TECHNIQUES; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FUSION PROTEINS, BCR-ABL; HLA-A ANTIGENS; HUMANS; INTERFERON TYPE II; KILLER CELLS, LYMPHOKINE-ACTIVATED; LEUKEMIA, LYMPHOCYTIC, ACUTE, L2; OLIGOPEPTIDES; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0037353343     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(02)00092-9     Document Type: Article

References (15)

1. Kolb J.H., Mittermuller J., Clemm C., Ledderooe C., Brehm G., Heim M.et al. Donor leukocyte infusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 76:1990;2462.
2. Collins R.H., Goldstein S., Giralt S., Levine J., Porter D., Drobyski W.et al. Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant. 26:2000;511.
3. Nakajima A., Tauchi T., Ohyashiki K. abl-specific tyrosine kinase inhibitor, STI571 in vitro, affects Ph-positive acute lymphoblastic leukemia and chronic myelogenous leukemia in blastic crisis. Leukemia. 15:2001;989.
4. Barrett A. Immune responses to chronic myeloid leukemia. Bone Marrow Transplant. 9:1992;305.
5. Pawelec G., Rehbein A., Schlotz E., de Silva P. Cellular immune responses to autologous chronic myelogenous leukemia cells in vitro. Cancer Immunol. Immunother. 42:1996;193.
6. Bocchia M., Wentworth P.A., Southwood S., Sidney J., McGraw K., Scheinberg D.A.et al. Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. Blood. 85:1995;2680.
7. Bocchia M., Korontsvit T., Xu Q., Mackinnon S., Yang S.Y., Sette A.et al. Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood. 87:1996;3587.
8. Ten Bosch G.J.A., Joosten A.M., Kessler J.H., Melief C.J.M., Leeksma O.C. Recognition of bcr-abl positive leukemia blasts by human CD4+ T cells elicited by primary in vitro immunization with a bcr-abl breakdown peptide. Blood. 88:1996;3522.
9. Yotnda P., Firat H., Garcia-Pons F., Garcia Z., Gourru G., Vernant J.-P.et al. Cytotoxic T cell response against the chimeric p210 bcr-abl protein in patients with chronic myelogenous leukemia. J. Clin. Invest. 101:1998;2290.
10. Clark R.E., Dodi I.A., Hill S.C., Lill J.R., Aubert G., Macintyre A.R.et al. Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the bcr-abl b3a2 fusion protein. Blood. 98:2001;2887.
11. Nieda M., Nicol A., Kikuchi A., Kashiwase K., Taylor K., Suzuki K.et al. Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukemia cells from patients with chronic myeloid leukemia. Blood. 91:1998;977.
12. Collins R.H., Shpilberg O., Drobyski W.R., Porter D.L., Gilralt S., Champlin R.et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J. Clin. Oncol. 15:1997;433.
13. *1501-restricted p190 minor bcr-abl (e1a2)-specific CD4+ T lymphocytes. Br. J. Haematol. 109:2000;435.
14. Clark S.S., McLaughlin J., Timmons M., Pendergast A.M., Ben-Neriah Y., Dow L.W.et al. Expression of a distinctive bcr-abl oncogene in Ph1-positive acute lymphocytic leukemia. Science. 239:1988;775.
15. Chelvanayagam G. A roadmap for HLA-A, HLA-B, and HLA-C peptide binding specificities. Immunogenetics. 45:1996;15.